Crescent Biopharma, Inc. CBIO PHARMA

Q: What is the current share price of Crescent Biopharma, Inc. (CBIO)?

As of 2026-09-19 21:16 PDT, Crescent Biopharma, Inc. (CBIO) trades at $20.46 on NasdaqCM. Its 52-week range is $8.94 to $26.98.

Q: What is the market capitalisation of CBIO?

Crescent Biopharma, Inc. (CBIO) has a market capitalisation of $759.97M on NasdaqCM.

Q: What is the P/E ratio of CBIO?

CBIO trades at a trailing price-to-earnings (P/E) ratio of -146.14. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.19.

Q: What is the return on equity (ROE) of CBIO?

CBIO has a return on equity (ROE) of -75.83%. Its return on capital employed (ROCE) is -74.74%.

Q: Is CBIO a good stock to buy?

This page provides a data-driven analysis of Crescent Biopharma, Inc. (CBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://crescentbiopharma.com

Company Profile ↓

$20.46

+47.19% 1Y

Mkt Cap$759.97M

P/E-146.14

P/B4.19

52W High$26.98

52W Low$8.94

Book Value$4.77

EPS (TTM)$-0.14

Company Overview

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Recent Developments

5-Year Trend Long-term compounding — revenue CAGR -3.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-3.72%
1 Year:	-

Stock Price Performance

1 Year:	+47.19%
6 Months:	+70.22%
3 Months:	+18.40%
1 Month:	+21.50%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 64% of range

$8.94 $26.98

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)65.13 · Neutral

Price Performance

1M+21.50%

3M+18.40%

6M+70.22%

1Y+47.19%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -3.7% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-146.14

Industry PE

24.83

Forward P/E

-7.78

PEG Ratio

Book Value

$4.77

Price to Book

4.19

P/S

62.49

EV/EBITDA

-4.17

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-3.72%

Profit 5Y

Revenue (YoY)

Earnings (YoY)

Profitability & Returns

ROCE

-74.74%

ROE

-75.83%

ROA

-64.06%

Profit Margin

0.00%

Op Margin

Gross Margin

100.00%

EPS (Latest Qtr)

$-0.74

EPS (TTM)

$-0.14

Balance Sheet & Liquidity

Debt/Equity

0.88

Quick Ratio

9.26

Current Ratio

9.66

Debt

$1.44M

Total Assets

$182.76M

Current Assets

Working Capital

Ownership

Promoter Holding

0.42%

Chg in Prom Hold

FII / Inst Holding

82.86%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$759.97M

Total Revenue (TTM)

$11.88M

EBITDA

$-170.03M

Free Cash Flow

$-72.45M

Operating Cash Flow

$-72.68M

Shares Outstanding

37.14M

Gross Margin

100.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CBIO Crescent Biopharma, Inc. PHARMA	20.46	-146.14	$759.97M	0.00%	-74.74%	-75.83%	-3.72%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	10.84M	1.04M	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21.03M	25.89M	102.34M	25.77M	26.36M
Operating Income	-7.17M	-	-7.58M	-8.09M	-7.89M	-	-7.97M	-8.24M	-8.18M	-	-12.15M	-12.15M	-12.52M	-	-15.13M	-16.82M	-14.11M	-	-8.11M	-14.11M	-13.73M	-14.28M	-14.40M	-17.34M	-14.66M	-13.35M	-8.77M	-10.94M	-8.93M	-9.81M	-11.12M	-10.36M	-11.23M	-	-14.22M	-21.03M	-25.89M	-91.49M	-24.73M	-26.36M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-20.71M	-24.58M	-90.34M	-23.22M	-24.77M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.07M	0	0	0	0
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-21.79M	-24.61M	-90.40M	-23.28M	-24.84M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-
Net Income	-7.17M	-8.88M	-7.55M	-8.07M	-7.85M	-8.33M	-7.93M	-8.14M	-7.95M	-9.26M	-11.51M	-11.28M	-11.58M	-13.91M	-14.08M	-15.83M	-13.25M	-14.73M	-7.66M	-14.08M	-13.72M	-14.27M	-14.40M	-17.33M	-14.65M	-13.27M	-8.52M	-10.36M	-8.26M	-9.20M	-10.74M	-10.10M	-9.82M	-	-15.15M	-21.79M	-24.61M	-92.40M	-23.28M	-24.84M
Diluted EPS	-0.38	-0.47	-	-0.41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.28	-0.28	-0.34	-0.28	-0.25	-0.16	-0.17	-0.13	-0.14	-0.04	-0.16	-0.15	-	-	-4.93	-1.27	-4.01	-0.70	-0.74
R&D Expense	5.04M	-	5.52M	5.78M	5.92M	-	5.88M	5.72M	5.78M	-	9.30M	9.30M	9.73M	-	11.77M	13.07M	10.72M	-	12.67M	9.87M	10.67M	11.15M	10.17M	13.28M	9.60M	7.97M	4.92M	5.42M	4.07M	5.29M	6.03M	6.29M	1.72M	14.03M	10.63M	12.08M	20.35M	-	17.90M	19.39M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	15.26M	3.99M	15.03M	20.07M	18.50K	-	-	-	10.16M	1.16M	75.00K	10.00K	-	10.84M
Operating Income	3.64M	-10.61M	-11.14M	-12.78M	-31.91M	-33.93M	-51.50M	-61.39M	-51.51M	-63.45M	-47.40M	-39.28M	-40.04M	-152.63M
Net Income	3.66M	-10.61M	-11.12M	-12.77M	-31.81M	-33.28M	-48.27M	-57.89M	-51.03M	-63.43M	-46.69M	-36.90M	-37.88M	-153.94M
Diluted EPS	0.33	-8.87	-0.60	-	-	-	-	-1.34	-1.12	-1.23	-0.89	-0.58	-0.59	-
R&D Expense	9.44M	11.70M	19.57M	25.05M	23.28M	24.10M	40.09M	47.03M	44.93M	47.49M	28.39M	20.07M	14.26M	138.09M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Sep 2024	Dec 2024	Dec 2025
Total Assets	-	-	5.28M	57.26M	48.46M	42.39M	128.58M	214.84M	167.97M	142.83M	94.35M	51.81M	45.32M	-	35.62M	240.29M
Total Equity	8.46M	12.53M	2.91M	50.80M	40.47M	35.30M	119.70M	205.46M	154.20M	128.22M	81.60M	42.93M	38.41M	0	-15.48M	203.01M
Cash & Equivalents	28.17M	17.37M	2.31M	55.20M	46.80M	40.04M	123.92M	209.92M	158.20M	137.04M	90.25M	47.87M	41.79M	-	34.77M	213.19M
Total Liabilities	-	-	2.38M	6.46M	7.99M	7.09M	8.88M	9.37M	13.77M	14.61M	12.74M	8.88M	6.90M	-	47.10M	37.28M
Current Liabilities	-	-	2.28M	6.46M	7.75M	6.33M	8.17M	8.76M	10.95M	12.43M	11.82M	8.88M	6.84M	-	9.61M	36.07M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-8.24M	-29.73M	-29.77M	-43.33M	-51.98M	-39.24M	-57.49M	-46.46M	-34.88M	-31.10M	-71.53M
Investing Cash Flow	-	-	-	-268.59K	-704.20K	-294.11K	-125.62K	-144.93K	-68.51K	-14.94K	-84.19K	-21.39K	20.03K	-72.92M
Financing Cash Flow	-	-	-	114.12K	23.67M	113.95M	129.45M	412.91K	18.14M	10.72M	4.16M	28.82M	5.40K	322.98M
Capital Expenditure	-316.18K	-82.09K	-212.60K	-268.59K	-704.20K	-294.11K	-125.62K	-144.93K	-68.51K	-14.94K	-84.19K	-21.39K	-9.97K	-919.00K
Free Cash Flow	-	-	-	-8.51M	-30.44M	-30.06M	-43.46M	-52.13M	-39.31M	-57.50M	-46.54M	-34.90M	-31.11M	-72.45M

Ratios (Annual)

Figures in %.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	23.8%	-265.7%	-74.1%	-63.7%	-172,505.3%	-	-	-	-506.8%	-5,470.7%	-63,204.4%	-392,752.9%	-	-1,407.5%
Net Margin %	24.0%	-265.6%	-74.0%	-63.6%	-171,945.1%	-	-	-	-502.1%	-5,469.0%	-62,251.7%	-368,994.2%	-	-1,419.6%
ROE %	29.2%	-364.8%	-21.9%	-31.6%	-90.1%	-27.8%	-23.5%	-37.5%	-39.8%	-77.7%	-108.8%	-96.1%	244.7%	-75.8%
ROCE %	-	-353.1%	-21.9%	-31.4%	-88.5%	-28.2%	-25.0%	-39.1%	-39.5%	-76.9%	-110.4%	-102.1%	-154.0%	-74.7%

Shareholding Pattern

Insiders

0.42%

Institutions

82.86%

Public Float

83.21%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	FMR, LLC	11.13%	4.13M	$69.82M
2	BVF Inc.	7.40%	2.75M	$46.43M
3	Fairmount Funds Management LLC	7.40%	2.75M	$46.41M
4	Venrock Adviser, LLC	5.74%	2.13M	$36.04M
5	Logos Global Management LP	5.12%	1.90M	$32.09M
6	FCPM III Services B.V.	4.52%	1.68M	$28.34M
7	Balyasny Asset Management LP	4.48%	1.66M	$28.09M
8	Vestal Point Capital, LP	4.39%	1.63M	$27.53M
9	Opaleye Management Inc.	3.55%	1.32M	$22.28M
10	Blackrock Inc.	3.42%	1.27M	$21.48M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CBIO

Google News Mon, 31 Aug 2026

$CBIO stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQbldFWElKc2lKaEE4M2s1TGdWckQ5MGIxWDUzbU96c3VzNk0zRU5RaGZNM3Bid1Exa1d1M3o1WVBvZks5NmdmdXU2VDVkSE1pNjk0d2R5QnJ6MndUNXEwZ0hGXzlLbzFlcnJiQ2VrZTJoaWh4bVFTRkpJbWUwVHBxRTBzaEt2ejhUczY4Z3…

Google News hu, 23 Jul 2026

Two Crescent Biopharma Employees Receive 52,500 Stock Options - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPU3VPYW1CcFFZRnZRNnhEUzdyWktGcjhQeG82czNkVGtMa0t0X1M5MTJjWm9uV21ZR1Zwd1VYQXA0dzVyWmZpSVNoVXU2WVo1WkhBVXY5dFAwaU1kM0dNUWVxcDBZSFduc2RySi1Ga3JsMlFUOUFGU2g4cFJkYTFOcHgyWTBhR0tIb2hOVG…

Google News ue, 26 May 2026

CBIO - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBzS2t2VmwyQ0x1bktCeWRMbmpTaWdwX1JxOWV3czZUeG9OU0lkbm0yYlVVcDJlQUsxZnAtZHRPdmRkbkdmNXc?oc=5" target="_blank">CBIO</a>  <font color="#6f6f6f">Finviz</font>…

Google News Fri, 03 Apr 2026

Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree - Trefis

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQV09BbGpZclhid29hckFEMVBpZ1pOQUVENjhOelZIci0wa05WQ0xDdTJDeTE1cTc4bmtCc2ROazNHajUySzhFZkNJX1N1U2VJcHBtSUtFYlJuMl9zbmhOM0hDbmlYMDZRQ0stdjRRMEg2dTJicVBXcXdwcVZENzZJSkVZbnEyam5fR3RCaE…

Google News Mon, 06 Jul 2026

Price to sales forward of Crescent Biopharma, Inc. – NASDAQ:CBIO - tradingview.com

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOYnhCdkFRUS0yMm1HRWZZRXk0LXp1aV84dF90cHJZaERSRmxjdFdjMzd0M1NFUFlFOWdWTHM4a1ozdVZiX3llZkhXMVk1Q2g5WEJ6S3FvVEllUTV5QjV2ZzRndkpGdEE1TVV6RjdHc3h4VG5mb0lXdkRrSmh2Nk54R1R2UW1QRjRUOE93SF…

Google News Mon, 01 Jun 2026

Crescent Biopharma Rings the Nasdaq Stock Market Closing Bell - Nasdaq

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOQlNWRlpoUG93SDV1a2dzWkJwQjE4TExNUVU4Tk13aUxKQmZ5RVhET3dzYVpsNmpMZVpqQ2U1eUVTeFNmSGJBLUFCU2d5SmZ1QTZxWDVOWnViMS1yd3hkelo3ekEyeEJmb3hnVmNrWFQzYTZWNXVXclFZTWRHamtZcXBNQ1lfcTlCbHA0bV…

CBIO — Frequently Asked Questions

What is the current share price of Crescent Biopharma, Inc. (CBIO)?

As of 2026-09-19 21:16 PDT, Crescent Biopharma, Inc. (CBIO) trades at $20.46 on NasdaqCM. Its 52-week range is $8.94 to $26.98.

What is the market capitalisation of CBIO?

Crescent Biopharma, Inc. (CBIO) has a market capitalisation of $759.97M on NasdaqCM.

What is the P/E ratio of CBIO?

CBIO trades at a trailing price-to-earnings (P/E) ratio of -146.14. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.19.

What is the return on equity (ROE) of CBIO?

CBIO has a return on equity (ROE) of -75.83%. Its return on capital employed (ROCE) is -74.74%.

Is CBIO a good stock to buy?

This page provides a data-driven analysis of Crescent Biopharma, Inc. (CBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Crescent Biopharma, Inc. CBIO PHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

$CBIO stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Two Crescent Biopharma Employees Receive 52,500 Stock Options - Stock Titan

CBIO - Finviz

Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree - Trefis

Price to sales forward of Crescent Biopharma, Inc. – NASDAQ:CBIO - tradingview.com

Crescent Biopharma Rings the Nasdaq Stock Market Closing Bell - Nasdaq

CBIO — Frequently Asked Questions

What is the current share price of Crescent Biopharma, Inc. (CBIO)?

What is the market capitalisation of CBIO?

What is the P/E ratio of CBIO?

What is the return on equity (ROE) of CBIO?

Is CBIO a good stock to buy?

Explore More